CD147 Expression Indicates Unfavourable Prognosis in Prostate Cancer

Abstract

Extracellular matrix metalloproteinase inducer (EMMPRIN, also named as CD147) is a multifunctional membrane glycoprotein over-expressed in many kinds of human solid tumors. It has been demonstrated to be involved in tumor invasion and angiogenesis. The aim of this study was to analyze the clinicopathological characteristics of the expression of CD147 in human prostate cancer (PCa), and to evaluate its clinical significance in the histologic classification and prognosis of PCa. CD147 protein expression in paraffin-embedded specimens gathered from 62 cases of PCa and 30 cases of benign prostatic hyperplasia (BPH) were detected by the method of immunohistochemistry. The association of CD147 protein expression with the clinicopathological characteristics and with the prognosis of PCa was subsequently assessed. CD147 expression were positively expressed in 51/62 (82.3%) of PCa and 4/30 (13.3%) of BPH cases, respectively. The positive expression rate of CD147 in PCa tissues was significantly higher than that in BPH. The positive expression of CD147 was dramatically associated with TNM grade (p < 0.001), the depth of the prostatic wall invasion (p = 0.008), GLEASON Score (p = 0.001) and Histologic grade (p = 0.001). The patients with CD147 expression were associated with a poor prognosis of PCa (p = 0.01) and the survival rate of the patients with a strong positive expression of CD147 was the lowest (p = 0.01). The results suggest that the expression of CD147 may be an important feature of PCa and the detection of its expression may benefit us in the prediction of the prognosis of PCa.

Inhibition of Proliferation, Invasion, and Migration of Prostate Cancer Cells by Downregulating Elongation Factor-1α Expression

“…Diagnosis and treatment of PCa has had many advances in the past 20 years; unfortunately, the existing treatment approaches and surgical interventions have been proven to be inadequate for the management of this disease (1,2). PCa deaths are a result of metastatic disease and treatment of such metastatic disease is one of the major therapeutic challenges.…”

Aberrant hypomethylation-mediated CD147 overexpression promotes aggressive tumor progression in human prostate cancer

“…Especially in PCa, Wang et al (20) found that CD147 downregulation by RNAi technology could decrease the invasive capability of the PCa cells; data of our research group (21) and Madigan et al (22) both showed that CD147 could regulate MMPs and was involved in PCa progression. Hao et al (23) also reported that CD147 expression may be correlated with drug resistance during PCa metastasis and may be a useful potential therapeutic target in advanced disease; our research group further identified the potential role of CD147 as an independent predictor of biochemical recurrence, development of metastasis and reduced overall survival in PCa (24,25). However, the mechanisms that result in the aberrant expression of CD147 in PCa are not fully elucidated.…”

Expression and clinical significance of extracellular matrix metalloproteinase inducer, EMMPRIN/CD147, in human osteosarcoma

“…Previous studies have shown that EMMPRIN/CD147, through multiple pathways and mechanisms, stimulates adjacent fibroblasts to produce matrix metalloproteinases, and thus promotes survival, invasion and metastasis of tumor cells (13,(18)(19)(20)(21)(22)(23)36). Indeed, EMMPRIN/CD147 expression is correlated significantly with the stage of clinicopathology in thyroid carcinoma (9), adenocarcinomas (7), esophageal squamous cell carcinomas (37) and prostate cancer (14). Furthermore, treatment with anti-EMMPRIN/CD147 antibody delays the formation of tumors in animal models (38).…”

“…EMMPRIN/CD147 is a highly glycosylated transmembrane protein belonging to the immunoglobulin superfamily 34 and is widely presented and/or overexpressed on the membrane surface of various malignant tumor cells (7,8,(10)(11)(12)(13)(14)(15)(16)(17). Due to its close association with pathological classification and overall survival analysis, EMMPRIN/CD147 has been potentially suggested as a prognostic factor in certain types of malignant tumors (7,8,10,(12)(13)(14)(15)17,(21)(22)(23)(24). In the present study, our results indicated that EMMPRIN/CD147 was expressed not only in all three human osteosarcoma cell lines, but also in the cell membrance and cytoplasm of osteosarcoma tissues from the majority of patients pathologically diagnosed with osteosarcoma at grade IIA or above.…”

“…Extracellular matrix metalloproteinase inducer (EMMPRIN, also known as CD147, EMMPRIN/CD147) is a highly glycosylated transmembrane protein and is abundantly expressed on the membrane surface of various tumor cells, including non-small cell lung cancer (NSCLC) (7), macrophage-like lymphoid neoplasm P388D1 cells (8), thyroid carcinoma (9), primary cutaneous malignant melanoma (10), intrahepatic cholangiocarcinoma (11), colorectal/gastric cancer (12), renal cell carcinoma (13), prostate cancer (14), cervical cancer (15), epithelial ovarian cancer (16) and breast carcinoma (17). EMMPRIN/CD147 promotes survival, invasion and metastasis of tumor cells through multiple pathways and mechanisms, including the functional loss of p53, a tumor suppressor (18), upregulated expression of vascular endothelial growth factor (VEGF) (13,(19)(20)(21), disruption of transforming growth factor-β1 (TGF-β1), a growth-modulating factor (22), and regulation of the urokinase-type plasminogen activation (uPA) system of serine proteases (23).…”